Skip to main content
BTSG
NASDAQ Industrial Applications And Services

BrightSpring Q2 2026: Revenue Jumps 23%, Net Income Surges to $87M, Leverage Drops to 2.15x

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$73
Mkt Cap
$14.303B
52W Low
$19.01
52W High
$73.75
52W Position info
284% above low
Off High info
1.0% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BTSG has more than doubled off its 52-week low of $19.01.

Summary

BrightSpring reported Q2 2026 revenue of $3.87B (+23% YoY) and net income of $86.6M, driven by strong pharmacy and provider growth. Leverage fell to 2.15x after a $300M debt paydown.


Key Events · Earnings and Guidance · BTSG

  • Revenue Surges 23% to $3.87B

    Q2 2026 total revenue grew 23% year-over-year to $3.87 billion, with Pharmacy Solutions up 22% to $3.4 billion and Provider Services up 30% to $466 million, driven by specialty drug volume and the Amedisys acquisition.

  • Net Income Swings to $86.6M

    Net income from continuing operations was $86.6 million, compared to $8.5 million in Q2 2025. Diluted EPS from continuing operations rose to $0.39 from $0.04.

  • Adjusted EBITDA Up 44% to $205.5M

    Adjusted EBITDA increased 44.2% to $205.5 million, with segment EBITDA growth of 44% in Pharmacy Solutions and 33% in Provider Services.

  • Leverage Reduced to 2.15x After $300M Debt Paydown

    The company used proceeds from the Community Living divestiture to repay $300 million of term debt and refinanced the remaining balance at SOFR + 2.00%, reducing leverage from 2.99x at year-end 2025 to 2.15x.


Analysis · BTSG · Industrial Applications And Services

A blowout quarter underscores BrightSpring's accelerating momentum. Revenue climbed 23% to $3.87 billion, while net income from continuing operations swung dramatically from $8.5 million to $86.6 million. Both segments delivered robust growth—Pharmacy Solutions revenue rose 22% on specialty drug volume, and Provider Services grew 30%, boosted by the Amedisys acquisition. Proceeds from the Community Living divestiture allowed the company to pay down $300 million in debt and refinance its term loan at a lower rate, cutting leverage to 2.15x. Liquidity now stands at over $1 billion. The results confirm the business is scaling profitably and deleveraging rapidly, though the secondary offering by KKR and management in June signals ongoing sponsor exit.

At the time of this filing, BTSG was trading at $73.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $14.3B. The 52-week trading range was $19.01 to $73.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BTSG - Latest Insights

BTSG
Jul 31, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $73.20
Real-time Price: $73.00 info
Change: -$0.200 (-0.27%) info
Market Cap: $14.303B info
BTSG
Jul 31, 2026, 6:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $72.12
Real-time Price: $73.00 info
Change: +$0.880 (+1%) info
Market Cap: $14.303B info
BTSG
Jun 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $63.23
Real-time Price: $73.00 info
Change: +$9.77 (+15%) info
Market Cap: $14.303B info
BTSG
Jun 10, 2026, 1:34 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $61.12
Real-time Price: $73.00 info
Change: +$11.88 (+19%) info
Market Cap: $14.303B info
BTSG
Jun 05, 2026, 5:21 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $58.00
Real-time Price: $73.00 info
Change: +$15.00 (+26%) info
Market Cap: $14.303B info